Teva Sees COVID Sales Correction

Takes Impairment On Japanese Venture And Bolsters Biosimilars Business

 
• By Dave Wallace

In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.

Balancing_Coins_Covid
A Q2 decline due to COVID-19 balanced out a spike in demand from Q1 • Source: Shutterstock

More from Earnings

More from Business